Quote | Aprea Therapeutics Inc. (NYSE:APRE)
Last: | $ |
---|---|
Change Percent: | -0.29% |
Open: | $34.88 |
Close: | $34.52 |
High: | $36.00 |
Low: | $34.11 |
Volume: | 25,629 |
Last Trade Date Time: | 02/12/2020 04:44:03 pm |
News | Aprea Therapeutics Inc. (NYSE:APRE)
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
Message Board Posts | Aprea Therapeutics Inc. (NYSE:APRE)
Subject | By | Source | When |
---|---|---|---|
Dropping like a waterfall. | willlbone | investorshub | 11/11/2022 4:07:04 PM |
$APRE is climbing, it climbed today in spite | Nazirite | investorshub | 07/11/2022 8:22:41 PM |
Price target set for $3 buy and hold | Nazirite | investorshub | 07/11/2022 1:25:09 PM |
GM $APRE time to work | Nazirite | investorshub | 07/11/2022 12:51:35 PM |
High volume today 43x avg | Nazirite | investorshub | 07/08/2022 3:52:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
Aprea Therapeutics Inc. Website:
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it will host a virtual KOL...
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need Dosing of the first patient in the ACESOT-1051 study represent...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...